Form 4: Adicet Bio Director Adjusts Stock Option Prices Following Repricing Rescission

Jeffrey Chodakewitz, a director at Adicet Bio, adjusted his stock option holdings on August 21, 2024, following the board's decision to rescind a previous repricing of stock options for non-employee directors.

Summary

• On August 21, 2024, Adicet Bio director Jeffrey Chodakewitz engaged in transactions involving stock options.
• These transactions were a result of the Issuer's Board of Directors approving a rescission of the August 2023 stock option repricing for certain non-employee directors.
• The affected stock options were reverted to their original exercise prices as established at the time of the grant.
• Chodakewitz acquired and disposed of multiple tranches of stock options with varying exercise prices and expiration dates.
• The transactions did not involve any monetary exchange, as the price is listed as $0.00 for both acquisitions and disposals.
• The shares subject to these options are fully vested and exercisable as of August 21, 2024.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting transactions. The rescission of the repricing could be seen as a positive move towards fairness, but it's not a major event.

Positives

• The adjustment of stock options back to their original prices could be seen as a move towards fairer compensation for non-employee directors.
• The fact that the shares are fully vested and exercisable provides immediate potential value to the director.

Future Outlook

The document does not contain specific forward-looking statements, but the stock option adjustments suggest an ongoing effort to manage director compensation.

Management Comments

• The Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer.
• All of the affected stock options have been reverted to their original exercise price as established at the time of the grant.

Industry Context

Stock option repricing and subsequent rescission are not uncommon in the biotech industry, often used to incentivize directors and employees. This filing reflects a corporate governance decision related to director compensation.

Comparison to Industry Standards

• Stock option plans are a standard component of compensation packages for directors in biotech companies like Adicet Bio.
• Repricing of stock options is a tool sometimes used when a company's stock price has declined significantly, but it can also be controversial.
• Companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) also used stock options extensively to incentivize employees and directors, but the specific terms and conditions vary widely.

Corporate Governance

Stakeholder Impact

• The adjustment of stock options may have a minor impact on shareholder equity.
• The change primarily affects the compensation of non-employee directors.

Key Dates